259 related articles for article (PubMed ID: 25092961)
1. Treatment of vascular activity secondary to atypical choroidal nevus using intravitreal bevacizumab.
Cavalcante ML; Villegas VM; Gold AS; Cavalcante LL; Lonngi M; Shah NV; Murray TG
Clin Ophthalmol; 2014; 8():1377-82. PubMed ID: 25092961
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Bevacizumab for Traumatic Choroidal Rupture.
Kim M; Kim JH; Seo Y; Koh HJ; Lee SC
Optom Vis Sci; 2015 Oct; 92(10):e363-7. PubMed ID: 26367340
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for choroidal neovascularization associated with choroidal nevus.
Chiang A; Bianciotto C; Maguire JI; Park CH; Baker PS; Shields JA; Shields CL
Retina; 2012 Jan; 32(1):60-7. PubMed ID: 21886019
[TBL] [Abstract][Full Text] [Related]
8. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
9. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
11. Bilateral choroidal neovascularization associated with gyrate atrophy managed with intravitreal bevacizumab.
Inanc M; Tekin K; Teke MY
Int Ophthalmol; 2018 Jun; 38(3):1351-1355. PubMed ID: 28560651
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization.
Mandal S; Venkatesh P; Sampangi R; Garg S
Eur J Ophthalmol; 2007; 17(4):620-6. PubMed ID: 17671940
[TBL] [Abstract][Full Text] [Related]
13. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma.
De Benedetto U; Battaglia Parodi M; Knutsson KA; Librando A; Bandello F; Lanzetta P; Iacono P
J Ocul Pharmacol Ther; 2012 Oct; 28(5):550-2. PubMed ID: 22554238
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
17. Anatomical and visual outcome of intravitreal bevacizumab (Avastin) in patients with diabetic macular edema.
Vyas S; Thapa R; Bajimaya S; Pradhan E; Paudyal G
Nepal J Ophthalmol; 2016 Jan; 8(15):54-61. PubMed ID: 28242886
[TBL] [Abstract][Full Text] [Related]
18. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
19. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.
Amaro MH; Roller AB
Arq Bras Oftalmol; 2012; 75(4):273-6. PubMed ID: 23258660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
